Cargando…

Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial

AIM: Anticoagulation prophylaxis for stroke is recommended for at-risk patients with either persistent or paroxysmal atrial fibrillation (AF). We compared outcomes in patients with persistent vs. paroxysmal AF receiving oral anticoagulation. METHODS AND RESULTS: Patients randomized in the Rivaroxaba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steinberg, Benjamin A., Hellkamp, Anne S., Lokhnygina, Yuliya, Patel, Manesh R., Breithardt, Günter, Hankey, Graeme J., Becker, Richard C., Singer, Daniel E., Halperin, Jonathan L., Hacke, Werner, Nessel, Christopher C., Berkowitz, Scott D., Mahaffey, Kenneth W., Fox, Keith A.A., Califf, Robert M., Piccini, Jonathan P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313363/ https://www.ncbi.nlm.nih.gov/pubmed/25209598 http://dx.doi.org/10.1093/eurheartj/ehu359

Ejemplares similares

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
por: Singer, Daniel E., et al.
Publicado: (2015)

Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
por: Singer, Daniel E., et al.
Publicado: (2013)

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
por: Piccini, Jonathan P., et al.
Publicado: (2014)

Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF
por: DeVore, Adam D., et al.
Publicado: (2016)

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
por: Breithardt, Günter, et al.
Publicado: (2014)

Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
por: Ugowe, Francis E., et al.
Publicado: (2021)

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
por: Leef, George C., et al.
Publicado: (2017)

Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
por: Carnicelli, Anthony P., et al.
Publicado: (2021)

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF
por: Ungar, Leo, et al.
Publicado: (2019)

Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial
por: Quinn, Gene R., et al.
Publicado: (2018)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
por: Steinberg, Benjamin A, et al.
Publicado: (2015)

Mapping and Imaging in Non-paroxysmal AF
por: Ghannam, Michael, et al.
Publicado: (2019)

ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015)

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
por: Pokorney, Sean D., et al.
Publicado: (2016)

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
por: Lim, Toon Wei, et al.
Publicado: (2023)

Opposite evolution on voltage and thickness from paroxysmal to persistent AF
por: Silva Garcia, E, et al.
Publicado: (2023)

Make : Rockets : down-to-earth rocket science
por: Westerfield, Mike
Publicado: (2014)

Rocketing into the future: the history and technology of rocket planes
por: van Pelt, Michel
Publicado: (2012)

Diagnostic values of different ECG durations in paroxysmal AF diagnosis
por: Li, Qian, et al.
Publicado: (2021)

Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry
por: Perino, Alexander C., et al.
Publicado: (2019)

It is rocket science, then
por: Cookson, C
Publicado: (2003)

Rockets and missiles
por: Taylor, John W R
Publicado: (1970)

Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
por: Steinberg, Benjamin A., et al.
Publicado: (2015)

Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry
por: Fosbol, Emil L., et al.
Publicado: (2013)

Experimental validation of rotating detonation for rocket propulsion
por: Bennewitz, John W., et al.
Publicado: (2023)

Management of acute stroke in patients taking novel oral anticoagulants
por: Hankey, Graeme J, et al.
Publicado: (2014)

Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
por: Thomas, Kevin L., et al.
Publicado: (2017)

The flight of uncontrolled rockets
por: Gantmakher, F R, et al.
Publicado: (1964)

Materials for rockets and missiles
por: Frank, Robert G, et al.
Publicado: (1959)

Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
por: Steinberg, Benjamin A., et al.
Publicado: (2018)

Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
por: Washam, Jeffrey B., et al.
Publicado: (2018)

Role of diagnosis-to-ablation time in paroxysmal atrial fibrillation: preliminary results of the MULTI AF trial
por: Rossi, L, et al.
Publicado: (2023)

Clinical Characteristics To Guide The Extent Of Ablation In Paroxysmal AF Patients: Discovering An Old Science
por: Brooks, Anthony G, et al.
Publicado: (2009)

Changes in LA volume and diameter correlate with mechanisms of recurrence after paroxysmal AF ablation
por: Buffle, Eric, et al.
Publicado: (2022)

AIM‐AF: A Physician Survey in the United States and Europe
por: Camm, A. John, et al.
Publicado: (2022)

Nuclear Rocket Engine Reactor
por: Lanin, Anatoly
Publicado: (2013)

Fundamentals of aircraft and rocket propulsion
por: El-Sayed, Ahmed F
Publicado: (2016)

Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA(2)DS(2)‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
por: Jackson, Larry R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hrb62k0c1k2k0t6u4ku049ecl6